RE:RE:Merck ditches oncolytic virus Cavatak Could be that Meck has ditched intratumorally injected Cavatak and may be looking at ONCY's intravenously administered Immune Molecule Platform Technology pelareorep given the newly opened Phase 1/2 AMBUSH trial involving pelareorep in combinbination with Merck's (MSD) immune checkpoint inhibitor pembrolizumab (Keytruda) in Multiple Myeloma (MM) started in August 2022 - and could be looking at ONCY as an M&A acquisition target.
Biotechs are usually bought out by big pharmaceutical companies who have the financial muscle to fund large phase 3 clinical trials and commercialise successful treatments. The conditions appear ripe for an M&A boom: big drugmakers are sitting on almost $300 Billion of cash with S1.25 Trillion in firepower, and many, including Merck and Bristol-Myers-Squibb, need to refill their pipelines because of major patent expiries in the second half of the decade.
https://clinicaltrials.gov/ct2/show/NCT05514990